Navigation Links
Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Date:10/16/2008

BERLIN, October 16 /PRNewswire/ -- Berlin Heart Inc. today announced its EXCOR(R) Pediatric ventricular assist device (VAD) has received unconditional approval for the ongoing IDE clinical trial in the United States of America. The U.S Food and Drug Administration (FDA) has fully approved the Investigational Plan for the IDE study of the device.

In 2007, the FDA had granted conditional approval for the prospective IDE study to begin initially at 10 centres with 10 patients, while the company addressed some questions the FDA had found after reviewing the study design. "The FDA has worked effectively with Berlin Heart to refine the design of the trial to optimize the potential for a meaningful study with useful conclusions," stated Bob Kroslowitz, Vice President of Clinical Affairs for North America at Berlin Heart.

The Berlin Heart EXCOR Pediatric is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. Unlike standard heart-lung machines, EXCOR Pediatric has been used as a short-term, mid-term, and long-term support system, supporting failing hearts from days up to several months.

The system is designed to bridge patients awaiting heart transplantation until a donor heart becomes available, but has also been used successfully as a bridge to recovery when a patient's heart was able to recover and work on its own again. Unlike other VADs, EXCOR Pediatric can be used to support children of all age groups, from newborns up to teenagers.

Sven-Rene Friedel, the company's CEO, comments, "The FDA's Unconditional Approval of the IDE study represents a major milestone for the company. The approval moves us closer to our goal of making the device more readily available in the US." Bob Kroslowitz adds, "The study is progressing extremely well and we are confident it will provide positive results. Our next step is to activate the remaining IDE study sites."

Dr. Charles D. Fraser, J
'/>"/>

SOURCE Berlin Heart AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
2. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
3. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
4. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
5. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
6. Curemark Appoints Preeminent Pediatrics Gastroenterologist
7. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
8. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
9. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
10. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
11. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
(Date:7/30/2014)... Hayward, CA (PRWEB) July 30, 2014 ... and accessories at the lowest prices on the internet ... Lightning Cables in two lengths and two colors. These ... performance standards. , The high quality SF Cable ... 8-pin connector with digital signal delivering faster charging and ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... Some obese people have a genetic mutation that seems ... when they see food, researchers report. Gaining a ... pleasure and gratification at the sight of high-calorie foods ... overeating, the scientists suggested. More than one-third of ... by a combination of overeating, a lack of physical ...
(Date:7/30/2014)... KY (PRWEB) July 30, 2014 DRE ... pleased to announce the launch of its Medical ... online resource for medical professionals and equipment vendors. , ... shows and conventions in the United States and around ... the calendar, and that number is always growing. , ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... metabolisms, which may help them generate the energy they need ... in the July Cell Metabolism , a Cell Press ... before detectable tumors form. By the same token, the studies ... metabolism shifts back before established tumors shrink. "This ...
... colorectal cancer risk, according to a new study in ... Gastroenterological Association (AGA) Institute. Folate is a water-soluble B ... that all forms and sources of folate were associated ... PhD, of the American Cancer Society and lead author ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... age 2 generally aren,t at risk for future behavioral or ... Kids who are speech-delayed, but don,t have any other developmental ... at age 2. But, the study found, those problems don,t ...
... , TUESDAY, July 5 (HealthDay News) -- People with ... increased risk of death, a new study indicates. ... January 2006 and September 2010 -- that looked at ... specified. Anorexics mistakenly believe they are fat and ...
... include Western lung cancer patients, first-line treatment with ... chemotherapy, according to research presented at the 14th ... by the International Association for the Study of ... kinase inhibitor (TKI) that targets the epidermal growth ...
... ingredients for long-term relationship satisfaction, according to an international ... committed relationships, but contrary to stereotypes, tenderness was more ... Also contrary to expectations of the researchers, men ... relationship, while women were more likely to report being ...
Cached Medicine News:Health News:Metabolic shift may offer early cancer clue 2Health News:High folate intake may reduce risk of colorectal cancer 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 3Health News:Eating Disorders Appear to Raise Risk of Death 2Health News:EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 3
... The 9115-5.0 transducer ... transducer imaging at the ... (patented) HST technology, this ... quality when higher frequency ...
TOX/See is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
Medicine Products: